Moderna Inc. (MRNA), a leading provider of COVID-19 vaccines, saw their stock drop 6.6% in premarket trading on Friday. This was due to news that one of their flu vaccine candidates had failed to meet the desired goal in a trial. Despite this news, Stephen Hoge, the President of Moderna, was optimistic about the future of the vaccine. He stated that “we have already updated the vaccine that we believe could improve immune responses against Influenza B and will seek to quickly confirm those improvements in an upcoming clinical study thanks to the agility of our mRNA platform”.
The news of Moderna’s trial failure comes at a time when the number of new COVID-19 cases in the United States is decreasing. According to the New York Times tracker, the seven-day average of new U.S. COVID cases was at 37,775 on Thursday, a 9% decrease from two weeks ago. The daily average for hospitalizations was down 8% at 28,795. The average for deaths was 398, down 14% from two weeks ago.
Globally, the number of confirmed cases of COVID-19 has surpassed 673.7 million, with the death toll reaching 6.86 million according to data aggregated by Johns Hopkins University. The United States has the highest number of cases and deaths in the world, with 103 million cases and 1,117,113 fatalities.
The news of Moderna’s failed trial of their flu vaccine candidate is a setback for the company, but it also highlights the importance of continuing to develop more effective vaccines to combat the virus. The decrease in new cases of COVID-19 in the United States is encouraging, but it is clear that the virus is still a major threat to public health. Vaccines are a key tool in the fight against the virus, and companies like Moderna are working to develop more effective vaccines to protect people from the virus.
Moderna has been a leader in the development of COVID-19 vaccines, and their mRNA platform provides them with the agility to quickly develop and test new vaccines. Despite the setback of their failed trial of their flu vaccine candidate, Moderna is still optimistic about the future of their vaccines. They are continuing to work to develop more effective vaccines to protect people from the virus, and their vaccine platform provides them with the agility to quickly develop and test new vaccines.
The news of Moderna’s failed trial of their flu vaccine candidate is a reminder of the importance of continuing to develop more effective vaccines to combat the virus. Despite the decreasing number of new cases in the United States, the virus is still a major threat to public health. Vaccines are a key tool in the fight against the virus, and companies like Moderna are working hard to develop more effective vaccines to protect people from the virus. With their mRNA platform, Moderna is well-positioned to quickly develop and test new vaccines, and they remain optimistic about the future of their vaccines.
